Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HARVARD BIOSCIENCE INCHBIO · Entity 7369 | Director | March 23, 2021 | March 26, 2021 |
| Harvard Apparatus Regenerative Technology, Inc.BSTG · Entity 7501 | Director | March 14, 2017 | March 16, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HARVARD BIOSCIENCE INC
Report date March 23, 2021 · Filed March 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 323,344 |
Reported balance
After 2021-03-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-03-23 · Gift · Disposed 6,895 · Balance 323,344 F1: This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift. F2: Includes (a) a deferred stock award of 13,200 restricted stock units which vest quarterly in equal installments on March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021 and are subject to continued service as a non-employee director on the applicable vesting dates, (b) an award of 28,100 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after June 11, 2020, immediately prior to the commencement of such meeting, or (ii) June 18, 2021, and (c) 282,044 shares of common stock held by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift.
F2: Includes (a) a deferred stock award of 13,200 restricted stock units which vest quarterly in equal installments on March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021 and are subject to continued service as a non-employee director on the applicable vesting dates, (b) an award of 28,100 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after June 11, 2020, immediately prior to the commencement of such meeting, or (ii) June 18, 2021, and (c) 282,044 shares of common stock held by the Reporting Person.
Harvard Apparatus Regenerative Technology, Inc.
Report date March 14, 2017 · Filed March 16, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2027-03-14 | Direct | 25,000 |
Reported balance
After 2017-03-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-14 · Grant · Acquired 25,000 · Balance 25,000 F1: The option shares vest in full one year from the date of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 18,250 |
Reported balance
After 2017-03-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-03-14 · Grant · Acquired 18,250 · Balance 18,250 F2: Restricted stock units granted by the Issuer pursuant to its 2013 Equity Incentive Plan and qualified under Rule 16b-3(d). Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F3: The restricted stock units vest and settle in full one year from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shares vest in full one year from the date of grant.
F2: Restricted stock units granted by the Issuer pursuant to its 2013 Equity Incentive Plan and qualified under Rule 16b-3(d). Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer.
F3: The restricted stock units vest and settle in full one year from the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2021 Filed Mar 26, 2021 23:41 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GiftCommon Stock | 6,895 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-21-000870 · form412799001_03262021.xml · nonDerivative · entry 1 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,344 F1 · price: This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift. F2 · balance_after: Includes (a) a deferred stock award of 13,200 restricted stock units which vest quarterly in equal installments on March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021 and are subject to continued service as a non-employee director on the applicable vesting dates, (b) an award of 28,100 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after June 11, 2020, immediately prior to the commencement of such meeting, or (ii) June 18, 2021, and (c) 282,044 shares of common stock held by the Reporting Person. Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 20:13 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GiftCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-21-000798 · form412799hbio_03192021.xml · nonDerivative · entry 2 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,239 F3 · price: This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift. F4 · balance_after: Includes (a) the shares and awards described in footnote (2) above, less (b) the disposition of shares reported in footnote (3) above. Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 20:13 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GiftCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-21-000798 · form412799hbio_03192021.xml · nonDerivative · entry 1 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,489 F1 · price: This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift. F2 · balance_after: Includes (a) a deferred stock award of 13,200 restricted stock units which vest quarterly in equal installments on March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021 and are subject to continued service as a non-employee director on the applicable vesting dates, (b) an award of 28,100 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after June 11, 2020, immediately prior to the commencement of such meeting, or (ii) June 18, 2021, and (c) 295,189 shares of common stock held by the Reporting Person. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:44 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 13,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-21-000050 · form412799ken_01062021.xml · nonDerivative · entry 1 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,739 F1 · shares: Represents a deferred stock award of 13,200 restricted stock units which vest quarterly in equal installments on March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021 and are subject to continued service as a non-employee director on the applicable vesting dates. These retainer awards are granted in satisfaction of the annual retainer compensation to be earned by the director for his service on the Issuer's Board of Directors and its Committees during 2021. The number of shares of common stock subject to such retainer award is equal to the amount of cash that would have been received had the applicable retainer all been paid in cash, divided by the average daily closing price of the Issuer's common stock for the month of November, rounded to the nearest 100 shares. F2 · balance_after: Includes (a) the award described in footnote (1) above, (b) an award of 28,100 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after June 11, 2020, immediately prior to the commencement of such meeting, or (ii) June 18, 2021, and (c) 301,439 shares of common stock held by the Reporting Person. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 22:59 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GiftCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-046013 · doc4.xml · nonDerivative · entry 1 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,539 F1 · price: This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift. F2 · balance_after: Includes (a) an award of 28,100 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after June 11, 2020, immediately prior to the commencement of such meeting, and (ii) June 18, 2021, (b) an award of 8,900 remaining unvested restricted stock units vesting in equal quarterly installments on September 30, 2020 and December 31, 2020, and (c) 292,539 shares of common stock held by the Reporting Person. Read SEC document |
| July 30, 2020 Filed Aug 4, 2020 22:00 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GiftCommon Stock | 6,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-044793 · doc4.xml · nonDerivative · entry 1 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,039 F1 · price: This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift. F2 · balance_after: Includes (a) an award of 28,100 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after June 11, 2020, immediately prior to the commencement of such meeting, and (ii) June 18, 2021, (b) an award of 8,900 remaining unvested restricted stock units vesting in equal quarterly installments on September 30, 2020 and December 31, 2020, and (c) 300,039 shares of common stock held by the Reporting Person. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 20:15 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GiftCommon Stock | 6,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043472 · doc4.xml · nonDerivative · entry 1 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,869 F1 · price: This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift. F2 · balance_after: Includes (a) an award of 28,100 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after June 11, 2020, immediately prior to the commencement of such meeting, and (ii) June 18, 2021, (b) an award of 8,900 remaining unvested restricted stock units vesting in equal quarterly installments on September 30, 2020 and December 31, 2020, and (c) 306,869 shares of common stock held by the Reporting Person. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:15 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GiftCommon Stock | 6,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-042808 · doc4.xml · nonDerivative · entry 1 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,699 F1 · price: This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift. F2 · balance_after: Includes (a) an award of 28,100 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after June 11, 2020, immediately prior to the commencement of such meeting, and (ii) June 18, 2021, (b) an award of 8,900 remaining unvested restricted stock units vesting in equal quarterly installments on September 30, 2020 and December 31, 2020, and (c) 313,699 shares of common stock held by the Reporting Person. Read SEC document |
| July 08, 2020 Filed Jul 14, 2020 20:15 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GiftCommon Stock | 6,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-042357 · doc4.xml · nonDerivative · entry 1 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,529 F1 · price: This transaction involved a gift of securities by the reporting person. Purchase price is not applicable as this transaction was a bona fide gift. F2 · balance_after: Includes (a) an award of 28,100 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after June 11, 2020, immediately prior to the commencement of such meeting, and (ii) June 18, 2021, (b) an award of 8,900 remaining unvested restricted stock units vesting in equal quarterly installments on September 30, 2020 and December 31, 2020, and (c) 320,529 shares of common stock held by the Reporting Person. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 21:15 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 28,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037995 · doc4.xml · nonDerivative · entry 2 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,359 F3 · shares: Represents an award of 28,100 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after June 11, 2020, immediately prior to the commencement of such meeting, and (ii) June 18, 2021. F4 · balance_after: Includes (a) the shares and awards described in footnote (2) above, and (b) the award described in footnote (3) above. Read SEC document |
| June 11, 2020 Filed Jun 19, 2020 21:15 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Disposition to issuerCommon Stock | 3,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037995 · doc4.xml · nonDerivative · entry 1 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,259 F1 · shares: On January 2, 2020, the Reporting Person received a retainer award of 24,200 restricted stock units of the Issuer, vesting in four equal installments on March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020. 6,400 of the restricted stock units were granted in connection with the Reporting Person's serving as chair of the Issuer's Audit Committee. On June 11, 2020, the Reporting Person stepped down from serving as chair of the Audit Committee, remaining as a member. In accordance with the Issuer's non- employee director compensation policy, the Reporting Person forfeited 3,534 restricted stock units as a result of the committee change. F2 · balance_after: Includes (a) a restricted stock unit award of 13,350 remaining unvested restricted stock units vesting in equal quarterly installments on June 30, 2020, September 30, 2020 and December 31, 2020, and (b) 322,909 shares of common stock held by the Reporting Person. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:28 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 24,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-000977 · doc4.xml · nonDerivative · entry 1 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,793 F1 · shares: Represents a deferred stock award of 24,200 restricted stock units which vest quarterly in equal installments on March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020, and are subject to continued service as a non-employee director on the applicable vesting dates. These retainer awards are granted in satisfaction of the annual retainer compensation to be earned by the director for his service on the Issuer's Board of Directors and its Committees during 2020. The number of shares of common stock subject to such retainer award is equal to the amount of cash that would have been received had the applicable retainer all been paid in cash, divided by the average daily closing price of the Issuer's common stock for the month of November, rounded to the nearest 100 shares. F2 · balance_after: Includes (a) a deferred stock award of 24,200 restricted stock units which vest quarterly in equal installments on March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020 as described in footnote 1 above, (b) a deferred stock award of 35,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 16, 2019, immediately prior to the commencement of such meeting, and (ii) May 23, 2020; and (c) 280,493 shares of common stock held by the Reporting Person. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:27 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 35,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-032793 · doc4.xml · nonDerivative · entry 1 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,593 F1 · shares: Represents a deferred stock award of 35,100 restricted stock units which fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 16, 2019, immediately prior to the commencement of such meeting, and (ii) May 23, 2020. F2 · balance_after: Includes (a) deferred stock award of 35,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 16, 2019, immediately prior to the commencement of such meeting, and (ii) May 23, 2020; (b) a deferred stock award of 13,275 restricted stock units which vest quarterly in equal installments on June 30, 2019, September 30, 2019 and December 31, 2019; and (c) 267,218 shares of common stock held by the Reporting Person. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:28 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 17,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-000968 · doc4.xml · nonDerivative · entry 1 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,493 F1 · shares: Represents a deferred stock award of 17,700 restricted stock units which vest quarterly in equal installments on March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019, and are subject to continued service as a non-employee director on the applicable vesting dates. These retainer awards are granted in satisfaction of the annual retainer compensation to be earned by the director for his service on the Issuer's Board of Directors and its Committees during 2019. The number of shares of common stock subject to such retainer award is equal to the amount of cash that would have been received had the retainers all been paid in cash, divided by the average daily closing market price of the Issuer's common stock for the month of November, rounded to the nearest 100 shares. F2 · balance_after: Includes (a) a deferred stock award of 17,700 restricted stock units which vest quarterly in equal installments on March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019; a (b) deferred stock award of 18,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 17, 2018, immediately prior to the commencement of such meeting, and (ii) May 17, 2019; and (c) 244,693 shares of common stock held by the Reporting Person. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 21:11 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GiftCommon Stock | 47,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-063153 · doc4.xml · nonDerivative · entry 1 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,793 F1 · kind: This transaction involved gifts of securities by the reporting person. Purchase price is not applicable as these transactions were bona fide gifts. F2 · balance_after: Includes (a) a deferred stock award of 800 restricted stock units which vest on December 31, 2018; (b) a deferred stock award of 18,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 17, 2018, immediately prior to the commencement of such meeting, and (ii) May 17, 2019; (c) a deferred stock award of 3,475 restricted stock units which vest on December 31, 2018; and (d) 240,418 shares of common stock held by the Reporting Person. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:25 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 2,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035683 · doc4.xml · nonDerivative · entry 2 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,480 F3 · shares: Represents a deferred stock award of 2,400 restricted stock units which vest quarterly in equal installments on June 30, 2018, September 30, 2018 and December 31, 2018. This retainer award was granted in lieu and satisfaction of the annual cash retainer compensation to be earned by the director for his service on a committee of the Issuer's Board of Directors that the reporting person was appointed to following the 2018 Annual Meeting of Stockholders. The number of shares of common stock subject to such retainer award is equal to the amount of cash that would have been received had the applicable retainer all been paid in cash, divided by the average daily closing market price of the Issuer's common stock for the month of March, rounded to the nearest 100 shares. F4 · balance_after: Includes (a) a deferred stock award of 2,400 restricted stock units which vest quarterly in equal installments on June 30, 2018, September 30, 2018 and December 31, 2018 as described in footnote 3 above; (b) a deferred stock award of 18,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 17, 2018, immediately prior to the commencement of such meeting, and (ii) May 17, 2019; (c) a deferred stock award of 10,425 restricted stock units which vest quarterly in equal installments on June 30, 2018, September 30, 2018 and December 31, 2018; and (d) 279,555 shares of common stock held by the Reporting Person. Read SEC document |
| May 24, 2018 Filed May 29, 2018 20:45 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 18,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033862 · doc4.xml · nonDerivative · entry 1 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,730 F1 · shares: Represents a deferred stock award of 18,100 restricted stock units which fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 17, 2018, immediately prior to the commencement of such meeting, and (ii) May 24, 2019. F2 · balance_after: Includes (a) a deferred stock award of 18,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 17, 2018, immediately prior to the commencement of such meeting, and (ii) May 17, 2019; (b) a deferred stock award of 12,900 restricted stock units which vest quarterly in equal installments on June 30, 2018, September 30, 2018 and December 31, 2018; and (c) 278,730 shares of common stock held by the Reporting Person. Read SEC document |
| May 17, 2018 Filed Jun 5, 2018 20:25 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Disposition to issuerCommon Stock | 1,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035683 · doc4.xml · nonDerivative · entry 1 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,080 F1 · shares: The subject restricted stock units were granted to the reporting person on January 1, 2018 and were forfeited as a result of the reporting person no longer being the Chairman of the Compensation Committee of the Issuer. F2 · balance_after: Includes (a) a deferred stock award of 18,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 17, 2018, immediately prior to the commencement of such meeting, and (ii) May 17, 2019; (b) a deferred stock award of 10,425 restricted stock units which vest quarterly in equal installments on June 30, 2018, September 30, 2018 and December 31, 2018; and (c) 279,555 shares of common stock held by the Reporting Person. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 13:39 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 17,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001616 · doc4.xml · nonDerivative · entry 1 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,630 F1 · shares: Represents a deferred stock award of 17,200 restricted stock units which vest quarterly in equal installments on March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018, and are subject to continued service as a non-employee director on the applicable vesting dates. These retainer awards are granted in lieu and satisfaction of the annual cash retainer compensation to be earned by the director for his service on the Issuer's Board of Directors and its Committees during 2018. The number of shares of common stock subject to such retainer award is equal to the amount of cash that would have been received had the retainers all been paid in cash, divided by the average daily closing market price of the Issuer's common stock for the month of November, rounded to the nearest 100 shares. F2 · balance_after: Includes (a) a deferred stock award of 17,200 restricted stock units which vest quarterly in equal installments on March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018; (b) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; and (c) 243,130 shares of common stock held by the Reporting Person. Read SEC document |
| May 25, 2017 Filed May 31, 2017 00:42 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 31,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-036304 · doc4.xml · nonDerivative · entry 1 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,430 F1 · shares: Represents a deferred stock award of 31,300 restricted stock units which fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018. F2 · balance_after: Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 16,725 restricted stock units which vest quarterly in equal installments on June 30, 2017, September 30, 2017 and December 31, 2017; and (c) 226,405 shares of common stock held by the Reporting Person. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 16:17 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantRestricted Stock Units · Derivative | 18,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-015095 · v461955_4.xml · derivative · entry 2 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,250 Underlying: Common Stock, par value $0.01 per share · 18,250 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units granted by the Issuer pursuant to its 2013 Equity Incentive Plan and qualified under Rule 16b-3(d). Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F3 · derivative.exercise_date: The restricted stock units vest and settle in full one year from the date of grant. F3 · derivative.expiration_date: The restricted stock units vest and settle in full one year from the date of grant. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 16:17 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001144204-17-015095 · v461955_4.xml · derivative · entry 1 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock, par value $0.01 per share · 25,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: The option shares vest in full one year from the date of grant. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:45 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 22,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-001034 · doc4.xml · nonDerivative · entry 1 KENNEDY JOHN F · CIK 0001138315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,130 F1 · shares: Represents a deferred stock award of 22,300 restricted stock units which vest quarterly in equal installments on March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017, and are subject to continued service as a non-employee director on the applicable vesting dates. These retainer awards are granted in lieu and satisfaction of the annual cash retainer compensation to be earned by the director for his service on the Issuer's Board of Directors and its Committees during 2017. The number of shares of common stock subject to such retainer award is equal to the amount of cash that would have been received had the retainers all been paid in cash, divided by the average daily closing market price of the Issuer's common stock for the month of November, rounded to the nearest 100 shares. F2 · balance_after: Includes (a) a deferred stock award of 22,300 restricted stock units which vest quarterly in equal installments on March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017; (b) a deferred stock award of 25,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after July 1, 2016, immediately prior to the commencement of such meeting, and (ii) July 1, 2017; and (c) 195,530 shares of common stock held by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.